Canada Approves Hibsago as a Finite Therapy for Chronic Hepatitis B

Health Canada approved Hibsago (bepirovirsen), described as the first and only finite therapy indicated to achieve a functional cure of chronic hepatitis B. The treatment received Priority Review.